Literature DB >> 29517963

Non-replacement therapy for haemophilia treatment: fetching the east by the west.

Marco Marietta1, Mario Luppi1,2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29517963      PMCID： PMC6125232          DOI： 10.2450/2018.0032-18

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  14 in total

Review 1.  Present and future challanges in the treatment of haemophilia: a clinician's perspective.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.

Authors:  Jeongheon Yoon; Anja Schmidt; Ai-Hong Zhang; Christoph Königs; Yong Chan Kim; David W Scott
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

3.  Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.

Authors:  K John Pasi; Savita Rangarajan; Pencho Georgiev; Tim Mant; Michael D Creagh; Toshko Lissitchkov; David Bevan; Steve Austin; Charles R Hay; Inga Hegemann; Rashid Kazmi; Pratima Chowdary; Liana Gercheva-Kyuchukova; Vasily Mamonov; Margarita Timofeeva; Chang-Heok Soh; Pushkal Garg; Akshay Vaishnaw; Akin Akinc; Benny Sørensen; Margaret V Ragni
Journal:  N Engl J Med       Date:  2017-07-10       Impact factor: 91.245

4.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Authors:  Johannes Oldenburg; Johnny N Mahlangu; Benjamin Kim; Christophe Schmitt; Michael U Callaghan; Guy Young; Elena Santagostino; Rebecca Kruse-Jarres; Claude Negrier; Craig Kessler; Nancy Valente; Elina Asikanius; Gallia G Levy; Jerzy Windyga; Midori Shima
Journal:  N Engl J Med       Date:  2017-07-10       Impact factor: 91.245

5.  AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.

Authors:  Savita Rangarajan; Liron Walsh; Will Lester; David Perry; Bella Madan; Michael Laffan; Hua Yu; Christian Vettermann; Glenn F Pierce; Wing Y Wong; K John Pasi
Journal:  N Engl J Med       Date:  2017-12-09       Impact factor: 91.245

Review 6.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.

Authors:  Alfonso Iorio; Emanuela Marchesini; Maura Marcucci; Kent Stobart; Anthony Kc Chan
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

7.  Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.

Authors:  Wolfgang Miesbach; Karina Meijer; Michiel Coppens; Peter Kampmann; Robert Klamroth; Roger Schutgens; Marco Tangelder; Giancarlo Castaman; Joachim Schwäble; Halvard Bonig; Erhard Seifried; Federica Cattaneo; Christian Meyer; Frank W G Leebeek
Journal:  Blood       Date:  2017-12-15       Impact factor: 22.113

8.  Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.

Authors:  Midori Shima; Hideji Hanabusa; Masashi Taki; Tadashi Matsushita; Tetsuji Sato; Katsuyuki Fukutake; Naoki Fukazawa; Koichiro Yoneyama; Hiroki Yoshida; Keiji Nogami
Journal:  N Engl J Med       Date:  2016-05-26       Impact factor: 91.245

9.  Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.

Authors:  P Chowdary; S Lethagen; U Friedrich; B Brand; C Hay; F Abdul Karim; R Klamroth; P Knoebl; M Laffan; J Mahlangu; W Miesbach; J Dalsgaard Nielsen; M Martín-Salces; P Angchaisuksiri
Journal:  J Thromb Haemost       Date:  2015-04-06       Impact factor: 5.824

10.  Targeting anticoagulant protein S to improve hemostasis in hemophilia.

Authors:  Raja Prince; Luca Bologna; Mirko Manetti; Daniela Melchiorre; Irene Rosa; Natacha Dewarrat; Silvia Suardi; Poorya Amini; José A Fernández; Laurent Burnier; Claudia Quarroz; Maria Desiré Reina Caro; Yasuhiro Matsumura; Johanna A Kremer Hovinga; John H Griffin; Hans-Uwe Simon; Lidia Ibba-Manneschi; François Saller; Sara Calzavarini; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2018-01-09       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.